Physician profile
Michael Robert Pavlica
NPI 1699735613
$4,545.04
in general payments reported to CMS, 2019-2025
25 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $82.28 · 2021: $62.29 · 2022: $482 · 2023: $462 · 2024: $759 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,340.00 | 2019 | |
| Apellis Pharmaceuticals, INC. | $466.78 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $457.19 | 2020-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $414.48 | 2022-2025 | |
| Alcon Vision LLC | $355.37 | 2022-2025 | Argos, Tryptyr, Rhopressa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $304.44 | 2019-2020 | |
| Oyster Point Pharma, INC. | $181.93 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $168.94 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $108.40 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $100.04 | 2019-2024 | Cequa |
| Dompe US, INC. | $94.13 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $76.23 | 2021-2023 | Tepezza |
| Sight Sciences, INC. | $69.77 | 2022 | |
| Thea Pharma INC. | $63.26 | 2024-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $59.99 | 2024-2025 | Xdemvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.03 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $48.51 | 2024-2025 | |
| Amgen INC. | $38.69 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $33.78 | 2023-2024 | Dextenza |
| Alimera Sciences, INC. | $22.49 | 2023 | Iluvien |
| Genentech USA, INC. | $20.46 | 2023 | Vabysmo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $18.71 | 2019 | |
| Allergan, INC. | $15.75 | 2021 | |
| Aerie Pharmaceuticals, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pavlica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.